ExploreWatchlistsPricing
  1. JP-listed companies
  2. Daito Pharmaceutical Co., Ltd.
  3. Financials
  4. Revenue

Daito Pharmaceutical Co., Ltd. (4577)

Market cap
¥42.2B
P/E ratio
16.6x
Daito manufactures active pharmaceutical ingredients and prescription drugs for domestic and international pharmaceutical companies. The company offers an integrated production system from raw materials to final formulations.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue (Million JPY)YoY (%)
May 31, 202550,643+7.99%
May 31, 202446,895+3.98%
May 31, 202345,101+3.77%
May 31, 202243,464-10.78%
May 31, 202148,715+8.28%
May 31, 202044,991+9.38%
May 31, 201941,135+3.16%
May 31, 201839,876+4.98%
May 31, 201737,984+4.44%
May 31, 201636,371+6.79%
May 31, 201534,059+9.18%
May 31, 201431,196+7.74%
May 31, 201328,956+6.65%
May 31, 201227,151

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat